[show abstract]
[hide abstract]
ABSTRACT: To review new clinically relevant data regarding the cause and treatment of scleritis that has been identified over the past 36 months.
A recently described T-helper cell population, known as Th-17, has been implicated in scleritis. Large-scale, retrospective reviews of standard corticosteroid-sparing systemic therapies, published in the last few years, have demonstrated only moderate efficacy for any particular immunomodulatory agent, whereas new data have confirmed excellent efficacy and tolerability to subconjunctival corticosteroids.
Improved understanding of the immunopathophysiology of scleritis offers hope for future molecule-specific drug design. Data continue to support the use of local steroids as a reasonable therapeutic option for nonnecrotizing, noninfectious anterior scleritis.
Current opinion in ophthalmology 11/2010; 21(6):463-7. · 2.49 Impact Factor
